GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
MEDIVATION INC (MDVN) [hlAlert]

Rating:
Neutral MDVN
down 49.57 %

MEDIVATION INC (MDVN) downgraded to Neutral by JP Morgan

Posted on: Thursday,  Mar 4, 2010  8:25 AM ET by JP Morgan

JP Morgan rated Neutral MEDIVATION INC (NASDAQ: MDVN) on 03/04/2010. Previously JP Morgan rated Overweight MEDIVATION INC (NASDAQ: MDVN) on 10/29/2009.,
when the stock price was $12.85. Since then, MEDIVATION INC has lost 49.57% as of 03/04/2010's recent price of $6.48.
If you would have followed the previous JP Morgan's recommendation on MDVN, you would have lost 49.57% of your investment in 126 days.

Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three medical needs: Alzheimer?s disease, Huntington?s disease and castration-resistant prostate cancer. The Company has formed separate subsidiaries to hold the product candidates it is developing. The Company?s subsidiary Medivation Neurology, Inc. holds its Dimebon technology, and its subsidiary Medivation Prostate Therapeutics, Inc. holds its MDV300 series technology.

JPMorgan is a leading financial services firm with one of the largest client franchises in the world. We partner with our clients to offer the most complete and innovative solutions in the industry to help them achieve their goals. For more than 200 years, we have taken a long-term approach to our clients and to the way we conduct business. Our firm has grown considerably in scale and scope, but our commitment to our core principle of doing "only first-class business... in a first-class way" has never been stronger.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/4/2010 8:25 AM Hold
None
6.48
as of 12/31/2010
1 Week   
1 Month   
3 Months   
1 YTD down  -65.57 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/29/2009 8:25 AM Buy
None
12.85

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy